Roche Sees Cancer Combos Start To Deliver

Roche presented a strong second quarter and was able to highlight a positive debut of Tecentriq, its PD-L1 antagonist, which brought the Swiss group into the lauded programed-death checkpoint inhibitor field.

Schwan_Severin_1200x675
CEO Severin Schwan • Source: Roche

Roche said group sales increased 5% to CHF25bn in the six months to June 30, slightly ahead of expectations. Net income rose by 3% at constant currencies to CHF5.5bn. Pharmaceutical sales were up by 4% to CHF19.5bn, driven by oncology and immunology drugs.

Tecentriq (atezolizumab), which was approved by the FDA in May 2016 for bladder cancer, had revenues of CHF19m "in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By 

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By 

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.

More from Scrip

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.